Neupane, Niraj http://orcid.org/0009-0007-1415-2418
Thapa, Sangharsha http://orcid.org/0000-0002-3391-762X
Bhattarai, Abhinav http://orcid.org/0000-0002-2232-4124
Ahuja, Kriti
Schlam, Ilana
Mittal, Abhenil
Tolaney, Sara M.
Tarantino, Paolo http://orcid.org/0000-0001-8686-0228
Article History
Accepted: 27 September 2023
First Online: 8 November 2023
Declarations
:
: SMT has served as an advisor/consultant to Novartis, Pfizer, Merck, Lilly, Nektar, NanoString Technologies, AstraZeneca, Puma Biotechnology, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, OncoPep, Kyowa Hakko Kirin, Samsung Bioepis, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Chugai Pharma, Ellipses Pharma, Infinity, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, and ARC Therapeutics, and has received institutional research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Odonate Therapeutics, Sanofi, and Seattle Genetics. PT served as advisor/consultant for AstraZeneca, Daiichi Sankyo, Gilead, Genentech, Roche, and Eli Lilly. All other authors report no conflicts of interest to disclose.